Congen Pharma obtained a Chinese invention patent for dihydro-oat alkaloid, continuing to increase investment in scientific research and innovation.

Publish Time:

2024-02-06


Adhering to original innovation, continuously breaking through technological barriers, and starting the "speed-up" in 2024.

 

Recently, Congen Pharma has obtained another Chinese invention patent for its "Preparation method of 2-phenylacetylamino-benzoic acid derivatives". This technological achievement is a new breakthrough for Congen Pharma in its scientific research journey and has been applied to the production of the anti-sensitive soothing raw material dihydro avenanthramide (INCI name: Hydroxyphenylacetylaminobenzoic acid).

 

△Chinese Invention Patent, Patent No.: ZL 202211223770.3

In recent years, with the increasing awareness of sensitive skin care among consumers, anti-sensitive soothing has become a market hotspot. Among them, dihydro avenanthramide, due to its ability to inhibit histamine release and quickly relieve itching and redness, has been widely used in the cosmetics industry and is highly praised and favored by industry professionals.

For Chinese national beauty brands, solving the problem of "core" shortage is crucial. Patented raw materials are not only a multiple-choice question but also a must-answer question. Congen Pharma, based on scientific research and innovation, has successfully developed a new method for preparing dihydro avenanthramide through in-depth research and experiments. This method simplifies the preparation steps and significantly improves the purity and yield of dihydro avenanthramide, enabling brands to create higher-quality products and providing consumers with safer and more effective anti-sensitive soothing solutions. 
According to the test report, the dihydro avenanthramide produced using this patented process has a chemical purity >99%.

△Tongjun Pharmaceutical Dihydro Avenanthramide Chemical Purity Chromatogram

 

In addition, in the production process of dihydro avenanthramide using traditional methods, expensive condensing agents or highly polluting acyl chloride reagents are used, consuming a large amount of organic or inorganic bases. The process is complex, and a huge amount of three wastes are produced. This new process applied by Congen Pharma, by adopting a new synthesis path and controlling reaction conditions, successfully improves the purity and yield of the target product while reducing waste generation during production. This not only solves the problems and challenges in traditional processes but also demonstrates Tongjun Pharmaceutical's practice and adherence to the concept of sustainable development.

 

At the same time, Congen Pharma has launched a compound soothing agent, Calming ®  Jing An Shu. This product uses two patented technologies independently developed by Congen Pharma. It not only provides customers with a more comprehensive and efficient anti-sensitive soothing solution but also provides dual patent claims to enhance the product's market competitiveness.

 

The acquisition of this patent is a major innovation by Congen Pharma in the in-depth development of beauty efficacy raw materials. In the future, Congen Pharma will continue to leverage its advantages in technological research and development and green raw material production to help national beauty brands build core barriers, bring safer and more effective products to consumers, and jointly promote the high-quality and sustainable development of China's cosmetics industry.